sentences:
COVID-19 vaccine response in pregnant and lactating women: a cohort study BackgroundPregnant and lactating women were excluded from initial COVID-19 vaccine trials; thus, data to guide vaccine decision-making are lacking. We sought to evaluate the immunogenicity and reactogenicity of COVID-19 mRNA vaccination in pregnant and lactating women.

Methods131 reproductive-age vaccine recipients (84 pregnant, 31 lactating, and 16 non-pregnant) were enrolled in a prospective cohort study at two academic medical centers. Titers of SARS-CoV-2 Spike and RBD IgG, IgA and IgM were quantified in participant sera (N=131), umbilical cord sera (N=10), and breastmilk (N=31) at baseline, 2nd vaccine dose, 2-6 weeks post 2nd vaccine, and delivery by Luminex, and confirmed by ELISA. Titers were compared to pregnant women 4-12 weeks from native infection (N=37). Post-vaccination symptoms were assessed. Kruskal-Wallis tests and a mixed effects model, with correction for multiple comparisons, were used to assess differences between groups.

ResultsVaccine-induced immune responses were equivalent in pregnant and lactating vs non-pregnant women. All titers were higher than those induced by SARS-CoV-2 infection during pregnancy. Vaccine-generated antibodies were present in all umbilical cord blood and breastmilk samples. SARS-CoV-2 specific IgG, but not IgA, increased in maternal blood and breastmilk with vaccine boost. No differences were noted in reactogenicity across the groups.

ConclusionsCOVID-19 mRNA vaccines generated robust humoral immunity in pregnant and lactating women, with immunogenicity and reactogenicity similar to that observed in non-pregnant women. Vaccine-induced immune responses were significantly greater than the response to natural infection. Immune transfer to neonates occurred via placental and breastmilk.

labels: obstetrics and gynecology


sentences: Exploration of interethnic variation and repurposed drug efficacy in the treatment of SARS-CoV-2 Infection (COVID-19) The COVID-19 global pandemic has led to repurposing of drugs, with little underlying evidence for treatment safety and efficacy. This may increase complications for patients with acute viral respiratory infections. UGT1A1 and CYP2D6 enzymes are involved in the metabolism of atazanavir and fluvoxamine repurposed for COVID-19. This study aimed to elucidate the role of interethnic variation in these enzymes in the efficacy of repurposed drug therapies. A retrospective cohort of 101 Jordanian Arab samples were genotyped using Affymetrix DMET Plus Premier Package. Comprehensive global population genetic structure analyses were performed for CYP2D6 and UGT1A1 allele frequencies across multi-ethnic populations of over 131,000 global subjects from 417 published reports, revealing that Jordanian Arabs share the closest sequence homology to European and Near East populations. The East Asian populations have significantly over-representaiton of individuals with diplotype pairs for reduced atazanavir metabolism compared to the African populations and are more likely to show impaired UGT1A1 metabolism. East Asian populations are also 4.4x more likely to show impaired fluvoxamine metabolism than South Central Asian and Oceanian populations, and 8x more likely than other ancestry populations. The results here support previous findings that interethnic variation should be used for developing proper population-specific dosage guidelines.

labels: genetic and genomic medicine


sentences:
SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release SARS-CoV-2 causes acute respiratory distress that can progress to multiorgan failure and death in some patients. Although severe COVID-19 disease is linked to exuberant inflammation, how SARS-CoV-2 triggers inflammation is not understood. Monocytes are sentinel blood cells that sense invasive infection to form inflammasomes that activate caspase-1 and gasdermin D (GSDMD) pores, leading to inflammatory death (pyroptosis) and processing and release of IL-1 family cytokines, potent inflammatory mediators. Here we show that ~10% of blood monocytes in COVID-19 patients are dying and infected with SARS-CoV-2. Monocyte infection, which depends on antiviral antibodies, activates NLRP3 and AIM2 inflammasomes, caspase-1 and GSDMD cleavage and relocalization. Signs of pyroptosis (IL-1 family cytokines, LDH) in the plasma correlate with development of severe disease. Moreover, expression quantitative trait loci (eQTLs) linked to higher GSDMD expression increase the risk of severe COVID-19 disease (odds ratio, 1.3, p<0.005). These findings taken together suggest that antibody-mediated SARS-CoV-2 infection of monocytes triggers inflammation that contributes to severe COVID-19 disease pathogenesis.

One sentence summaryAntibody-mediated SARS-CoV-2 infection of monocytes activates inflammation and cytokine release.

labels: infectious diseases


sentences: A 1 to 1000 SARS-CoV-2 reinfection proportion in members of a large healthcare provider in Israel: a preliminary report With more than 100 million confirmed COVID-19 cases as of March 2021, reinfection is still considered to be rare. In light of increasing reports of reinfected COVID-19 patients, the need to better understand the real risk for reinfection is critical, with potential effects on public health policies aimed at containing the spread of SARS-CoV-2. In this descriptive preliminary report, we conducted a large-scale assessment on the country level of the possible occurrence of COVID-19 reinfection within the members of a large healthcare provider in Israel. Out of 149,735 individuals with a documented positive PCR test between March 2020 and January 2021, 154 had two positive PCR tests at least 100 days apart, reflecting a reinfection proportion of 1 per 1000. Given our strict inclusion criteria, we believe these numbers represent true reinfection incidence in MHS and should be clinically regarded as such.


sentences:
Apt interpretation of comprehensive lipoprotein data in large-scale epidemiology - disclosure of fundamental structural and metabolic relationships AimsQuantitative lipoprotein analytics by NMR spectroscopy is currently commonplace in large-scale studies. One methodology has become widespread and is currently being utilised also in large biobanks. It allows comprehensive characterisation of 14 lipoprotein subclasses, clinical lipids, apolipoprotein A-I and B. The details of these data are conceptualised here in relation to lipoprotein metabolism with particular attention to the fundamental characteristics of subclass particle numbers, lipid concentrations and compositional measures.

Methods and ResultsThe NMR methodology was applied to fasting serum samples from Northern Finland Birth Cohort 1966 and 1986 with 5,651 and 5,605 participants, respectively. All results were highly coherent between the cohorts. Circulating lipid concentrations in a particular lipoprotein subclass arise predominantly as the result of the circulating number of those subclass particles. The spherical lipoprotein particle shape, with a radially oriented surface monolayer, imposes size-dependent biophysical constraints for the lipid composition of individual subclass particles and inherently restricts the accommodation of metabolic changes via compositional modifications. The new finding that the relationship between lipoprotein subclass particle concentrations and the particle size is log-linear reveal that circulating lipoprotein particles are also under rather strict metabolic constraints for both their absolute and relative concentrations.

ConclusionThe fundamental structural and metabolic relationships between lipoprotein subclasses elucidated in this study empower detailed interpretation of lipoprotein metabolism. Understanding the intricate details of these extensive data is consequential for the precise interpretation of novel therapeutic opportunities and for fully utilising the potential of forthcoming analyses of genetic and metabolic data in extensive biobanks.

One-sentence SummaryNMR spectroscopy facilitates comprehensive characterisation of lipoprotein subclass metabolism and offers additional value to epidemiology, genetics and pharmacology in large-scale studies and biobanks.

Key MessagesO_LIThe circulating particle number of a lipoprotein subclass is the defining measure for its lipid concentrations; the particle lipid composition is only in a minor role. The relationship between circulating lipoprotein subclass particle concentrations and the particle size is log-linear.
C_LIO_LIThe overall structure of lipoprotein subclass particles with a spherical shape and an oriented surface monolayer poses strong size-dependent biomolecular constraints for their lipid composition.
C_LIO_LIThe circulating lipoprotein subclass particle concentrations in humans are metabolically constraint for both elemental absolute and relative concentration ranges.
C_LIO_LIThe smallest HDL particle concentrations are negatively associated with those of large HDL and generally the associations of the smallest HDL particles are similar to those of apolipoprotein B-containing particles.
C_LIO_LIThe apolipoprotein B-containing particles constitute less than 10% of all lipoprotein particles but carry around two thirds of circulating lipoprotein lipids. LDL and IDL particles amount to almost 90% of all apolipoprotein B-containing particles.
C_LIO_LIThe supplemental role of lipoprotein subclass data in cardiometabolic risk assessment is slight.
C_LIO_LIIn the current era of biobanks and big data, the combination of lipoprotein subclass data with drug-target Mendelian randomization analyses provides great scientific synergy, intricate details and potential cost savings in drug development.
C_LI

Graphical abstract / key messages

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=135 SRC="FIGDIR/small/21253123v1_ufig1.gif" ALT="Figure 1">
View larger version (53K):
org.highwire.dtl.DTLVardef@11450dorg.highwire.dtl.DTLVardef@1cc7d71org.highwire.dtl.DTLVardef@3fb9edorg.highwire.dtl.DTLVardef@1c7a1d1_HPS_FORMAT_FIGEXP  M_FIG C_FIG

labels: epidemiology


sentences:
Tocilizumab efficacy in COVID-19 patients is associated with respiratory severity-based stages BackgroundTocilizumab treatment is investigated, and effectiveness in ICU-admitted COVID-19 patients has been reported. Although controversy exists regarding the efficacy of tocilizumab treatment, it has been suggested that tocilizumab might show positive results depending on patient severity status. We examined an association between tocilizumab and distinct disease severity stages.

Methods and FindingsFrom March 3 to March 23 2020, 494 consecutively admitted COVID-19 patients received tocilizumab or standard treatment alone. Data were obtained retrospectively. Clinical respiratory severity (CRS) stages were defined by patient oxygenation status and were also associated to scores of WHO clinical progression scale. We categorized patients in three stages, mild/moderate CRS1 (FiSpO2<0.35; WHO score 5), moderate/severe CRS2 (FiO2=0.5/high flow mask; WHO score 6) and severe/critical CRS3 (FiO2<80%/high flow/prone position or mechanical ventilation; score>6). The primary outcome was the composite of death or ICU admission in patients of stages CRS1, CRS2, and CRS3, as well as in total patients. We also addressed mortality alone in total patients. Kaplan-Maier curves, Cox proportional regression and inverse probability weighting marginal structural models were used. We conducted the study from March 3 to April 7 2020 with broad-ranged severity patients; 167 tocilizumab-treated and 327 untreated. CRS1 patients showed no apparent benefit after treatment, while the risk of the primary outcome was greatly reduced in CRS2 treated participants ((HR=0.22; 95% CI (0.16-0.44)). Moreover, tocilizumab treatment was associated with significantly decreased CRS2 patient proportion that reached the outcome compared to non-treated controls (27.8.0% vs. 65.4%; p<0.001). Severe/critical CRS3 patients, also showed benefit after treatment (HR=0.38; 95% CI (0.16-90)), although not as robust as was that of CRS2 treated individuals. Tocilizumab was associated with reduced outcome risk in total patients (HR=0.42; 95% CI (0.26-0.66)) after CRS adjustment, but not if CRS classification was not accounted as confounding factor (HR=1.19; 95% CI (0.84-1.69)). The outcome of mortality alone upon tocilizumab treatment was significant (HR=0.58; 95% CI (0.35-0.96)) after accounting for CRS classification.

ConclusionsTocilizumab treatment is associated with reduced COVID-19 escalation in CRS2 patients, suggesting efficacy in moderate/severe non-ICU-admitted patients. CRS classification could represent an essential confounding factor in evaluating tocilizumab in studies of broad-ranged severity patients.


sentences:
Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland BackgroundIn December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now named B.1.1.7. Based on initial data from the UK and later data from other countries, this variant was estimated to have a transmission fitness advantage of around 40-80% [1, 2, 3].

AimThis study aims to estimate the transmission fitness advantage and the effective reproductive number of B.1.1.7 through time based on data from Switzerland.

MethodsWe generated whole genome sequences from 11.8% of all confirmed SARS-CoV-2 cases in Switzerland between 14 December 2020 and 11 March 2021. Based on these data, we determine the daily frequency of the B.1.1.7 variant and quantify the variants transmission fitness advantage on a national and a regional scale.

ResultsWe estimate B.1.1.7 had a transmission fitness advantage of 43-52% compared to the other variants circulating in Switzerland during the study period. Further, we estimate B.1.1.7 had a reproductive number above 1 from 01 January 2021 until the end of the study period, compared to below 1 for the other variants. Specifically, we estimate the reproductive number for B.1.1.7 was 1.24 [1.07-1.41] from 01 January until 17 January 2021 and 1.18 [1.06-1.30] from 18 January until 01 March 2021 based on the whole genome sequencing data. From 10 March to 16 March 2021, once B.1.1.7 was dominant, we estimate the reproductive number was 1.14 [1.00-1.26] based on all confirmed cases. For reference, Switzerland applied more non-pharmaceutical interventions to combat SARS-CoV-2 on 18 January 2021 and lifted some measures again on 01 March 2021.

ConclusionThe observed increase in B.1.1.7 frequency in Switzerland during the study period is as expected based on observations in the UK. In absolute numbers, B.1.1.7 increased exponentially with an estimated doubling time of around 2-3.5 weeks. To monitor the ongoing spread of B.1.1.7, our plots are available online.


sentences: A Comparative Analysis of Clinical Stage 3 COVID-19 Vaccines using Knowledge Representation The emergence of a novel SARS-CoV-2 coronavirus at the end of 2019 and its accelerated spread worldwide to become a pandemic has had, from the medical biotechnology point of view, an unprecedented global response, to the point that there are currently 176 vaccine candidates in preclinical stage, 66 in clinical stage, of which 19 are in phase 3, and 5 of these are massively applied worldwide. The purpose of the present work is to elaborate a hierarchical landscape of the current status of phase 3 vaccines, taking into account their attributes of technological platform, safety and efficacy. The methodology used was that of conceptual knowledge representation, resulting in, firstly, an appropriate classification of stage 3 vaccines, The Conceptual Lattice for COVID-19 vaccines, constructed according to how they relate to each other with respect to the set of their attributes. Secondly, the approach used allows proposing rational strategies for the design of heterologous vaccination schemes, which are urgently needed to control the pandemic.

labels: public and global health


sentences: COVID-19-associated school closures and related efforts to sustain education and subsidized meal programs, United States, February 18-June 30, 2020 Pre-emptive school closures are frontline community mitigation measures recommended by CDC for implementation during severe pandemics. This study describes the spatiotemporal patterns of publicly announced school closures implemented in response to the coronavirus disease 2019 (COVID-19) pandemic and assesses how public K-12 districts adjusted their methods of education delivery and provision of subsidized meals. During February 18-June 30, 2020, we used daily systematic media searches to identify publicly announced coronavirus disease 2019 (COVID-19)-related school closures lasting [≥]1 day in the United States (US). We also collected statewide school closure policies from state government websites. Data on distance learning and subsidized meal programs were collected from a stratified sample of 600 school districts. The first COVID-19-associated school closure occurred on February 27, 2020 in Washington state. By March 30, 2020, all but one US public school districts were closed, representing the first-ever nearly synchronous nationwide closure of public K-12 schools in the US. Approximately 100,000 public schools were closed for [≥]8 weeks because of COVID-19, affecting >50 million K-12 students. Of 600 districts sampled, the vast majority offered distance learning (91.0%) and continued provision of subsidized meal programs (78.8%) during the closures. Despite the sudden and prolonged nature of COVID-19-associated school closures, schools demonstrated flexibility by implementing distance learning and alternate methods to continue subsidized meal programs.


sentences:
Dynamic Training of a Novelty Classifier Algorithm for Real-Time Early Seizure Onset Detection The objective of this study was to develop an adaptive framework for seizure detection in real-time that is practical to use in the Epilepsy Monitoring Unit (EMU) as a warning signal, and whose output helps characterize epileptiform activity. Our framework uses a one-class Support Vector Machine (SVM) that is being trained dynamically according to past activity in all available channels. This is done to evaluate the novelty of the current instance according to previous activity. Our algorithm was tested on intracranial EEG from human epilepsy patients that are admitted to the EMU for presurgical evaluation. In this study, we compared multiple configurations for using a one-class SVM to assess if there is significance over specific neural features or electrode locations. Our results show our algorithm is capable of running in real-time and achieving a high performance for early seizure-onset detection with a low false-positive rate and robustness to different types of seizure-onset patterns as well as to the number of channels used. This algorithm offers a solution to warning systems in the EMU as well as a tool for seizure characterization during post-hoc analysis of intracranial EEG data for surgical resection of the epileptogenic network.

HighlightsO_LIThis study proposes a dynamic training algorithm that efficiently detects sudden novel changes in intracranial electroencephalographic activity, creating a reliable seizure onset detection algorithm that does not need prior training.
C_LIO_LIThe algorithm described has the capability to be implemented in real-time, independently of the number of channels that are being analyzed.
C_LIO_LIThe presented detector shows high performance and reliability to be easily implemented in the Epilepsy Monitoring Unit to quickly alert clinical staff of seizure events.
C_LI

labels: neurology


sentences: Explainable AI for Retinal Prostheses: Predicting Electrode Deactivation from Routine Clinical Measures To provide appropriate levels of stimulation, retinal prostheses must be calibrated to an individuals perceptual thresholds ( system fitting). Nonfunctional electrodes may then be deactivated to reduce power consumption and improve visual outcomes. However, thresholds vary drastically not just across electrodes but also over time, thus calling for a more flexible electrode deactivation strategy. Here we present an explainable artificial intelligence (XAI) model fit on a large longitudinal dataset that can 1) predict at which point in time the manufacturer chose to deactivate an electrode as a function of routine clinical measures ( predictors) and 2) reveal which of these predictors were most important. The model predicted electrode deactivation from clinical data with 60.8% accuracy. Performance increased to 75.3% with system fitting data, and to 84% when thresholds from follow-up examinations were available. The model further identified subject age and time since blindness onset as important predictors of electrode deactivation. An accurate XAI model of electrode deactivation that relies on routine clinical measures may benefit both the retinal implant and wider neuroprosthetics communities.

labels: health informatics


sentences:
SAMGEP: A Novel Method for Prediction of Phenotype Event Times Using the Electronic Health Record ObjectiveWhile there exist numerous methods to predict binary phenotypes using electronic health record (EHR) data, few exist for prediction of phenotype event times, or equivalently phenotype state progression. Estimating such quantities could enable more powerful use of EHR data for temporal analyses such as survival and disease progression. We propose Semi-supervised Adaptive Markov Gaussian Embedding Process (SAMGEP), a semi-supervised machine learning algorithm to predict phenotype event times using EHR data.

MethodsSAMGEP broadly consists of four steps: (i) assemble time-evolving EHR features predictive of the target phenotype event, (ii) optimize weights for combining raw features and feature embeddings into dense patient-timepoint embeddings, (iii) fit supervised and semi-supervised Markov Gaussian Process models to this embedding progression to predict marginal phenotype probabilities at each timepoint, and (iv) take a weighted average of these supervised and semi-supervised predictions. SAMGEP models latent phenotype states as a binary Markov process, conditional on which patient-timepoint embeddings are assumed to follow a Gaussian Process.

ResultsSAMGEP achieves significantly improved AUCs and F1 scores relative to common machine learning approaches in both simulations and a real-world task using EHR data to predict multiple sclerosis relapse. It is particularly adept at predicting a patients longitudinal phenotype course, which can be used to estimate population-level cumulative probability and count process estimators. Reassuringly, it is robust to a variety of generative model parameters.

DiscussionSAMGEPs event time predictions can be used to estimate accurate phenotype progression curves for use in downstream temporal analyses, such as a survival study for comparative effectiveness research.


sentences:
Performance and Operational Evaluation of the Access Bio CareStart Rapid Antigen Test in a High-throughput Drive-through Community Testing Site in Massachusetts BackgroundTo facilitate deployment of point-of-care testing for SARS-CoV-2, we evaluated the Access Bio CareStart COVID-19 Antigen test in a high-throughput, drive-through, free community testing site using anterior nasal (AN) swab RT-PCR for clinical testing.

MethodsConsenting symptomatic and asymptomatic children ([≤]18 years) and adults received dual AN swabs. CareStart testing was performed with temperature/humidity monitoring. All tests had two independent reads to assess inter-operator agreement. Patients with positive CareStart results were called and instructed to isolate pending RT-PCR results. The paired RT-PCR result was the reference for sensitivity and specificity calculations.

ResultsOf 1603 participants, 1245 adults and 253 children had paired RT-PCR/CareStart results and complete symptom data. 83% of adults and 87% of children were asymptomatic. CareStart sensitivity/specificity were 84.8% (95% confidence interval [CI] 71.1-93.7)/97.2% (92.0-99.4) and 85.7% (42.1-99.6)/89.5% (66.9-98.7) in adults and children, respectively, within 5 days of symptoms. Sensitivity/specificity were 50.0% (41.0-59.0)/99.1% (98.3-99.6) in asymptomatic adults and 51.4% (34.4-68.1)/97.8% (94.5-99.4) in asymptomatic children. Sensitivity in all 234 RT-PCR-positive people was 96.3% with cycle threshold (Ct) [≤]25, 79.6% with Ct [≤]30, and 61.4% with Ct [≤]35. All 21 false positive CareStart tests had faint but normal bands. Inter-operator agreement was 99.5%. Operational challenges included identification of faint test bands and inconsistent swab elution volumes.

ConclusionsCareStart had high sensitivity in people with Ct [≤]25 and moderate sensitivity in symptomatic people overall. Specificity was unexpectedly lower in symptomatic versus asymptomatic people. Excellent inter-operator agreement was observed, but operational challenges indicate that operator training is warranted.


sentences: Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation We identified a novel SARS-CoV-2 variant by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California. Named B.1.427/B.1.429 to denote its 2 lineages, the variant emerged around May 2020 and increased from 0% to >50% of sequenced cases from September 1, 2020 to January 29, 2021, exhibiting an 18.6-24% increase in transmissibility relative to wild-type circulating strains. The variant carries 3 mutations in the spike protein, including an L452R substitution. Our analyses revealed 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation found in the B.1.1.7, B.1.351, and P.1 variants. Antibody neutralization assays showed 4.0 to 6.7-fold and 2.0-fold decreases in neutralizing titers from convalescent patients and vaccine recipients, respectively. The increased prevalence of a more transmissible variant in California associated with decreased antibody neutralization warrants further investigation.


sentences: Modified Oxacillin Resistant Staphylococcus aureus detected in neonatal intensive care patients Active surveillance in our neonatal intensive care unit identified Staphylococcus aureus cultures from two infants with heterogeneity in methicillin resistance between isolated subclones lacking mecA and mecC. Whole-genome analysis of 4 modified (MODSA) and 4 methicillin-susceptible (MSSA) subclones for each culture identified either truncating mutations in the cyclic diadenosine monophosphate phosphodiesterase enzyme (GdpP), or a nonsynonymous substitution in penicillin binding protein 2 (PBP2). These cases highlight the difficulty in identifying non-mecA/non-mecC-mediated methicillin-resistance in clinical laboratories.


sentences: Early estimates of SARS-CoV-2 B.1.1.7 variant emergence in a university setting Recent identification of the highly transmissible novel SARS-CoV-2 variant in the United Kingdom (B.1.1.7) has raised concerns for renewed pandemic surges worldwide 1,2. B.1.1.7 was first identified in the US on December 29, 2020 and may become dominant by March 2021 3. However, the regional prevalence of B.1.1.7 is largely unknown because of limited molecular surveillance for SARS-CoV-2 4. Quantitative PCR data from a surveillance testing program on a large university campus with roughly 30,000 students provides local situational awareness at a pivotal moment in the COVID-19 pandemic.


sentences:
Shotgun mass spectrometry-based lipid profiling identifies and distinguishes between chronic inflammatory diseases BackgroundInflammation impacts several acute and chronic diseases causing localized stress and cell death, releasing tissue-specific lipids into the circulation from inflamed cells and tissues. The plasma lipidome may be expected to reflect the type of inflammation and the specific cells and tissues involved. However, deep lipid profiles of major chronic inflammatory diseases have not been compared.

MethodsWe compare the plasma lipidomes of patients suffering from two etiologically distinct chronic inflammatory diseases, atherosclerosis-related cardiovascular disease (CVD) including ischemic stroke (IS), and systemic lupus erythematosus (SLE), to each other and to age-matched controls. The controls had never suffered from any of these diseases. Blood plasma lipidomes were screened by a top-down shotgun MS-based analysis without liquid chromatographic separation. Lipid profiling based on MS was performed on a cohort of 427 individuals. The cohort constitutes 85 controls (control), 217 with cardiovascular disease (further classified into CVD 1-5), 21 ischemic stroke patients (IS), and 104 patients suffering from systemic lupus erythematosis (SLE). 596 lipids were profiled which were quality filtered for further evaluation and determination of potential biomarkers. Lipidomes were compared by linear regression and evaluated by machine learning classifiers.

ResultsMachine learning classifiers based on the plasma lipidomes of patients suffering from CVD and SLE allowed clear distinction of these two chronic inflammatory diseases from each other and from healthy age-matched controls and body mass index (BMI). We demonstrate convincing evidence for the capability of lipidomics to separate the studied chronic and inflammatory diseases from controls based on independent validation test set classification performance (CVD vs control - Sensitivity: 0.90, Specificity: 0.98; IS vs control - Sensitivity: 1.0, Specificity: 1.0; SLE vs control - Sensitivity: 1, Specificity: 0.88) and from each other (SLE vs CVD {square} Sensitivity: 0.91, Specificity: 1). Preliminary linear discriminant analysis plots using all data clearly separated the clinical groups from each other and from the controls. In addition, CVD severities, as classified into five clinical groups, were partially separable by linear discriminant analysis. Notably, significantly dysregulated lipids between pathological groups versus control displayed a reverse lipid regulation pattern compared to statin treated controls versus non treated controls.

ConclusionDysregulation of the plasma lipidome is characteristic of chronic inflammatory diseases. Lipid profiling accurately identifies the diseases and in the case of CVD also identifies sub-classes. Dysregulated lipids are partially but not fully counterbalanced by statin treatment.

labels: cardiovascular medicine


sentences: Rationale, protocol and baseline characteristics of the metabolome, microbiome, and dietary salt intervention study (MetaSalt) High sodium intake has been recognized as an important risk factor for hypertension, but the role of gut microbiota composition and metabolomic profiles in the association between dietary sodium intake and blood pressure (BP) is uncertain. The metabolome, microbiome, and dietary salt intervention study (MetaSalt) study was conducted to investigate whether low- and high-dietary sodium intake influences BP by changing the microbial and metabolomic profiles. This is a family-based, multicentre intervention study conducted in four rural field-centres across three provinces in rural Northern China. Probands with untreated prehypertension or stage-1 hypertension were identified through a community-based BP screening, and their family members included siblings, offspring, spouses and parents were subsequently included. During the dietary intervention, low-salt and high-salt diets were provided free of charge to all participants. A total of 529 participants in four field centres were included in our study, with a mean age of 48.1 years old, and about 36.7% of them were male, 76.5% had a middle school (69.5%) or higher (7.0%) diploma, 23.4% had a history of smoke, 24.4% were current drinkers. The mean systolic and diastolic BP levels in the baseline were 129.54 mm Hg and 81.02 mm Hg for all participants, and significantly decreased during the low-salt intervention and increased during the high-salt intervention. Our study is well placed to check the impacts of dietary sodium intake on microbial and metabolomic profiles, which will have important implications for discovering the mechanisms in the development of hypertension and subsequent cardiovascular disease.


sentences: COVID-19 vaccine distrust in Colombian university students: Frequency and associated variables The study aimed to know the frequency and variables associated with COVID-19 vaccine distrust in students of a Colombian university. A cross-sectional study was carried out which participated emerging adult students of a Colombian university. A total of 1,136 students between 18 and 29 years (M= 22.0, SD = 3.0); most of them were female (66.0%), non-health students (82.8%), low-income (79.0%), and residents of urban areas (84.9%). It was frequent low institutional trust (74.8%), low cognitive, social capital (27.9%), low fear of COVID-19 (49.5%), low perceived stress related to COVID-19 (83.5%), and high COVID-19 vaccine distrust (78.9%). Non-health carrier (Adjusted OR = 3.63, 95%CI 2.58-5.10), rural residence (AOR = 1.85, 95%CI 1.13-3.04), low income (AOR = 1.84, 95%CI 1.31-2.57), and perceived stress related to COVID-19 (AOR = 1.74, 95%CI 1.20-2.54) were related to high COVID-19 vaccine distrust. In conclusion, COVID-19 vaccine distrust is high among emerging adult Colombian university students. The COVID-19 vaccine distrust is related to non-health science carriers, rural residents, low-income, and low-perceived stress related to COVID-19. The COVID-19 related health literacy should be improved in students of this university considering socio-cultural background.


sentences:
COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar BackgroundThe objective of this study was to develop a Coronavirus Disease 2019 (COVID-19) risk score to guide targeted RT-PCR testing in Qatar.

MethodsThe Qatar national COVID-19 testing database was analyzed. This database includes a total of 2,688,232 RT-PCR tests conducted between February 5, 2020-January 27, 2021. Logistic regression analyses were implemented to identify predictors of infection and to derive the COVID-19 risk score, as a tool to identify those at highest risk of having the infection. Score cut-off was determined using the receiving operating characteristic (ROC) curve based on maximum sum of sensitivity and specificity. The scores performance diagnostics were assessed.

ResultsLogistic regression analysis identified age, sex, and nationality as significant predictors of infection and were included in the risk score. The scores scoring points were lower for females compared to males and higher for specific nationalities. The ROC curve was generated and the area under the curve was estimated at 0.63 (95% CI: 0.63-0.63). The score had a sensitivity of 59.4% (95% CI: 59.1%-59.7%), specificity of 61.1% (95% CI: 61.1%-61.2%), a positive predictive value of 10.9% (95% CI: 10.8%-10.9%), and a negative predictive value of 94.9% (94.9%-95.0%). The risk score derived early in the epidemic, based on data until only April 21, 2020, had a performance comparable to that of a score based on a year-long testing.

ConclusionsThe concept and utility of a COVID-19 risk score were demonstrated in Qatar. Such a public health tool, based on a set of non-invasive and easily captured variables can have considerable utility in optimizing testing and suppressing infection transmission, while maximizing efficiency and use of available resources.


sentences: Role of IL-23 neutralization in psoriasis: insights from a mechanistic PK/PD model and meta-analysis of clinical data Blocking of IL-23 has shown a profound effect on patient outcomes in psoriasis. The current IL-23 binding monoclonal antibodies show differences in dosing regimens, pharmacokinetics, affinity for the target, and efficacy outcomes in the clinic. The goal of the current work is to use a mechanistic pharmacokinetics/pharmacodynamics mathematical model to estimate projected free IL-23 neutralization for the different therapeutic molecules and connect it to clinical efficacy outcomes. The meta-analysis indicates a sigmoid-like relationship and suggests that the best current anti-IL23 antibodies are close to saturating the efficacy that can be achieved by this pathway in psoriasis.

labels: pharmacology and therapeutics


sentences:
A Fundamental Distinction in Early Neural Processing of Implicit Social Interpretation in Schizophrenia and Bipolar Disorder BackgroundSocial cognition impairment is a key phenomenon in serious mental disorders such as schizophrenia (SCZ) and bipolar disorder (BPD). Although genetic and neurobiological studies have suggested common neural correlates, here we hypothesized that a fundamental dissociation of social processing occurs at an early level in these conditions.

MethodsBased on the hypothesis that key structures in the social brain, namely the temporoparietal junction, should present distinctive features in SCZ and BPD during low-level social judgment, we conducted a case-control study in SCZ (n=20) and BPD (n=20) patients and controls (n=20), using task-based fMRI during a Theory-of-Mind (ToM) visual paradigm leading to interpretation of social meaning based on simple geometric figures.

ResultsWe found opposite neural responses in two core ToM regions : SCZ patients showed social content-related deactivation (relative to controls and BPD) of the right supramarginal gyrus, a region which activity is required to overcome egocentric "overmentalizing", while the opposite pattern was found in BPD; reverse patterns, relative to controls and SCZ, were found in the left posterior superior temporal gyrus, a region involved in inferring others intentions. Receiver-operating-characteristic curve analysis showed 88% accuracy in discriminating the two clinical groups based on these neural responses.

ConclusionsThese contrasting activation patterns of the temporoparietal junction in SCZ and BPD represent mechanistic differences of social cognitive dysfunction that may be explored as biomarkers or therapeutic targets.

labels: psychiatry and clinical psychology


sentences: Brain structure and function show distinct relations with genetic predispositions to mental health and cognition Mental health and cognitive achievement are partly heritable. To identify the underlying neural mechanisms, we associated genetic predispositions to various mental health and cognitive traits with a large set of structural and functional brain measures from the UK Biobank (N=36,799). We show that genetic predispositions to attention deficit hyperactivity disorder, smoking initiation, and cognitive traits have stronger associations with brain structure than with brain function, whereas genetic predispositions to most other psychiatric disorders have stronger associations with brain function than with brain structure. These results reveal that genetic predispositions to mental health and cognitive traits have distinct brain profiles.


sentences:
Categorizing the Status of COVID-19 Outbreaks Around the World Although the SARS-CoV-19 virus spread rapidly around in world in early 2020, disease epidemics in different places evolved differently as the year progressed - and the state of the COVID-19 pandemic now varies significantly across different countries and territories. We have created a taxonomy of possible categories of disease dynamics, and used the evolution of reported COVID-19 cases relative to changes in disease control measures, together with total reported cases and deaths, to allocate most countries and territories among the possible categories. As of 31 January 2021, we find that the disease was (1) kept out or suppressed quickly through quarantines and testing & tracing in 39 countries with 29 million people, (2) suppressed on one or more occasions through control measures in 74 countries with 2.49 billion people, (3) spread slowly but not suppressed, with cases still increasing or just past a peak, in 31 countries with 1.45 billion people, (4) spread through the population, but slowed a result of control measures, leading to a "flattened curve" and fewer infections than if the epidemic were unmitigated, in 32 countries with 2.24 billion people, and (5) spread through the population with some but limited mitigation in 5 countries with 168 million people. In addition, several countries have experienced increases in cases after disease appeared to have finished spreading due to declining numbers of susceptible people. For some of these countries - for example Kenya, Pakistan and Afghanistan - the resurgences can be explained by the relaxation of control measures (and may have been enhanced by disease spread in population segments that experienced lower infection levels during the first waves). For other countries, the resurgences point to the effects of new virus variants with higher transmissibility or immunity resistance - including most countries in Southern Africa (where the B.1.351 variant has been identified) and several countries in West Africa (potentially due to the B.1.1.7 or other variants). These findings are consistent with mounting evidence of high infection rates in several low- and middle-income countries, both from seroprevalence studies and estimates of actual deaths from COVID-19 combined with estimates of expected mortality rates. We estimate that 1.3-3.0 billion people, or 17-39% of the global population, have been infected by SARS-CoV-2 to date, and that at least 4.5 million people have died from COVID-19 - much higher than reported cases and deaths. Disease control policies and vaccination strategies should be designed based on the state of the COVID-19 epidemic in the population - and consequently may need to be different in different countries.

Key Points The state of the COVID-19 pandemic varies significantly in different countries and territories around the world - and policies for disease control and vaccination will need to be tailored accordingly.
In any epidemic, there are several possibilities for how the disease will spread over time - and our analysis finds that, in fact, as of 31 January 2021, there were many countries and territories in each of the main categories of COVID-19 epidemic dynamics that might have been expected:
O_LIKept out or suppressed quickly through quarantines and testing & tracing - in 39 countries with 29 million people (0.4% of the global population), mostly small island states and a few countries in Southeast Asia. [Category H in the following map and table]
C_LIO_LISuppressed through control measures (social distancing, hygiene and testing & tracing) -in 74 countries with 2.49 billion people (31.9% of global population), mostly in Europe, East Asia and the Pacific. [Categories F and G]
C_LIO_LISpread slowly but not suppressed, with cases still increasing or just past a peak - in 31 countries with 1.45 billion people (18.6% of global population), including many countries in Latin America, Eastern Europe and the Middle East, as well as the United States and Russia. [Categories D and E]
C_LIO_LISpread through the population, but slowed as a result of control measures, leading to a "flattened curve" and fewer infections than if the epidemic were unmitigated - in 32 countries with 2.24 billion people (28.8% of global population), mostly in South and Southeast Asia (including India) and Africa. [Category B]
C_LIO_LISpread through the population with some but limited mitigation or "flattening the curve" -in 5 countries with 168 million people (2.2% of global population). [Category A]
C_LIO_LIExperienced increases in cases after disease appeared to have finished spreading, which in some countries might have been solely due to relaxation of control measures (especially in wealthier population segments which experienced low infection levels during the first wave) - for example in Kenya and in Pakistan and some Central Asian countries - but which in some countries is likely to be due to new virus variants with higher transmissibility or immunity resistance - for example in most countries in Southern Africa and several in West Africa, and possibly also in parts of South and Central America. [Category J and many countries in Category K]
C_LI
These findings are backed up by mounting evidence of high infection rates in several low- and middle-income countries. Seroprevalence studies in Kenya, Nigeria, Pakistan and South Africa have reported finding antibodies for SARS-CoV-2 in large percentages of the studied populations - and suggest that current infection levels are likely above 50% in each country. Studies of actual deaths due to COVID-19, combined with estimates of expected mortality rates, similarly suggest that SARS-CoV-2 has, by now, infected more than half of the populations in Bolivia, Ecuador, Peru, Mexico, South Africa, Sudan, Syria, Yemen and Zambia.
Countries of all income levels, and from all regions, appear in each of the main disease dynamics categories; however, there are clear income and geographical patterns in states of COVID-19 epidemics around the world. Most high-income countries have controlled the spread of SARS-CoV-2 through measures. Middle-income countries are spread across all categories, and account for 45 of the 63 countries which have slowed the disease significantly but not fully suppressed it. Some low-income have experienced largely unmitigated susceptibility-driven dynamics, while others have "flattened the curve" to varying degrees.
We estimate that between one and two out of every five people globally has been infected by SARS-CoV-2 to date, and that at least 4.5 million people have died from COVID-19. Our estimate of total infections - 1.3-3.0 billion people, or 17-39% of the global population - is between 13 and 30 times the number of confirmed cases, and twice to four times as much as previous estimates of total infection numbers. We estimate that 4.6-10.0 million people have died from COVID-19, between 2.1 and 4.5 times the number of deaths attributed to COVID-19.
An estimated 8.9-12.5 million lives remained at risk from COVID-19 as of the end of January 2021, prior to vaccination efforts - mainly in high-income countries (2.4-2.9 million), China (2.1 million) and India (1.7-2.9 million). Vaccinations, of course, have already started to reduce these numbers substantially.
Our analytical approach is simple but useful - providing insight into the epidemic status even in many low-income countries with limited disease monitoring, and with potential to provide early warnings of significant new variants. We compare the evolution of reported cases with changes in stringency of disease control measures, and check that infection levels are plausible given total reported cases and deaths and the income level of the country. Anomalies in which changes in the evolution of reported cases cannot be explained by changes in the stringency index provide indications of possible significant variants of the virus. Up to the end of January, the data provide indications of the presence of significant new variants in:
O_LIMost countries in Southern Africa (where the B.1.351 variant, with higher transmissibility and some resistance to immunity, was first identified in South Africa)
C_LIO_LISeveral countries in West Africa (likely with higher transmissibility and resistance to immunity, possibly the B.1.1.7 variant, which was first identified in the UK and has been found in Ghana and Nigeria, or possibly a different variant).
C_LI
They also suggest, with less certainty, that the disease dynamics may be affected by new variants in several countries in South and Central America (perhaps the P.1 variant descended from the B.1.1.28 variant which was first identified as coming from the Brazilian Amazon).
Different countries should adopt different disease control policies, according to the state of the COVID-19 epidemic in the population.
O_LIFor countries that have kept the disease out or suppressed outbreaks through control measures, their measures need to be kept in place - and potentially strengthened especially in the face of higher-transmissibility variants - until vaccines have been widely administered.
C_LIO_LIFor countries in which the disease is spreading slowly, full control measures should be maintained at least until new case numbers fully decline from the peak; later, it may be possible to relax some measures, but if measures are relaxed too soon or too much after cases peak, then significant further outbreaks can be expected (as has already happened in several such countries).
C_LIO_LIFor countries in which cases have declined following a flattened curve, there may be room to relax control measures that have the greatest negative health, economic and social consequences - but the most effective control measures will need to be maintained (even when cases remain low for extended periods), and measures may need to be strengthened to tackle variants which higher transmissibility or ability to evade immune responses.
C_LIO_LIFor countries in which the disease spread was largely unmitigated, many control measures could be relaxed for most people - although there may be risks if sizeable population segments have much lower infection levels than the general population or from variants with a high degree of immunity resistance.
C_LI
These findings may have implications for the optimal distribution of early batches of vaccines within countries.
O_LIFor countries that have kept the disease out or suppressed outbreaks through control measures, vaccinations should be given first to frontline healthcare and essential workers and to elderly and vulnerable groups (starting with the oldest and most vulnerable).
C_LIO_LIFor countries in which the disease is spreading slowly, detailed modelling should be done to determine whether the optimal strategy is to vaccinate at-risk groups first or to vaccinate key transmitters to halt the outbreak and "crush the curve" while waiting for further vaccine supplies to arrive. For any country choosing the key transmitter strategy - as Indonesia has done and has been suggested for the United States - it will be essential to maintain control measures, and to keep higher transmissibility variants out, or otherwise the benefits of a key transmitter vaccination strategy could be lost.
C_LIO_LIFor countries in which the cases declined following a flattened curve, vaccinations should probably be given first to elderly and vulnerable groups, but the optimal strategy may switch to vaccinating key transmitters if there are resurgences in cases due to higher-transmissibility or immunity-resistant variants.
C_LIO_LIFor countries in which the disease spread was largely unmitigated, vaccination should concentrate on elderly and vulnerable people, because population-level immunity already exists, and the greatest danger lies in vulnerable people becoming infected due to endemic SARS-CoV-2 from variants that will likely circulate over many years.
C_LI
These findings may also have implications for the optimal distribution of the first vaccines across countries. For most countries, the optimal allocation of vaccines doses is likely still to be according to population size - as current recommendations suggest. However, the global optimal allocation strategy might include providing somewhat greater supplies, during the next few months, to countries where using the vaccine to halt spread of the disease might be possible (provided that disease control measures are maintained in those countries).
Vaccination strategies will need to account for current and potential future virus variants as well as the likelihood that immunity from vaccination will wane over time. Higher-transmissibility variants of the SARS-CoV-2 virus increase the urgency of distributing vaccines in countries which have controlled the disease to date, and may alter the optimal strategy for countries deciding between vaccination first of elderly and vulnerable people or of key transmitters. Immunity-resistant variants of the virus may reduce the effectiveness of current vaccines, but are not likely to negate fully the protection they offer. Immunity acquired through vaccination is likely to wane over time - like immunity acquired through infection. In many, perhaps most, countries, the time to vaccinate the whole population will exceed the timeframe in which immunity from vaccination wanes or new immunity-resistant variants emerge. Looking to the longer term, therefore, new virus variants and waning immunity are likely to necessitate re-vaccination (with vaccines tailored to the latest variants) on a regular basis - and the optimal long-term strategies for ongoing vaccination will vary widely across countries and will depend on many factors.

O_FIG O_LINKSMALLFIG WIDTH=154 HEIGHT=200 SRC="FIGDIR/small/21252586v3_ufig1.gif" ALT="Figure 1">
View larger version (46K):
org.highwire.dtl.DTLVardef@c39b02org.highwire.dtl.DTLVardef@1f5ccceorg.highwire.dtl.DTLVardef@590b3dorg.highwire.dtl.DTLVardef@1f0f1c5_HPS_FORMAT_FIGEXP  M_FIG C_FIG O_FIG O_LINKSMALLFIG WIDTH=151 HEIGHT=200 SRC="FIGDIR/small/21252586v3_ufig2.gif" ALT="Figure 2">
View larger version (60K):
org.highwire.dtl.DTLVardef@190e169org.highwire.dtl.DTLVardef@bec2a2org.highwire.dtl.DTLVardef@1dc3cf0org.highwire.dtl.DTLVardef@24d56b_HPS_FORMAT_FIGEXP  M_FIG C_FIG SummaryThe state of the COVID-19 pandemic varies significantly in different countries and territories around the world - and policies for disease control and vaccination will need to be tailored accordingly. Although the SARS-CoV-19 virus spread rapidly around in world in early 2020, the state of disease epidemics in different countries diverged rapidly as the year progressed. Many high-income countries have had second or third waves; other countries have seen cases continue to increase gradually; still others have experienced declines in cases to low levels after peaks in mid-2020. Facing different situations, different countries might need to adopt different policies in the coming months, including different disease control measures and vaccination strategies.

Each country needs to know its COVID-19 status. There are several possible courses that a disease epidemic can take in a population. The disease can spread rapidly until its runs out of people remaining to infect; the disease can be slowed with control measures but still spread until large numbers of people are infected and immune; the disease can be suppressed or "crushed" by control measures; or the disease can be kept out completely. More complex disease dynamics will occur when a virus mutates, if new variants evade immune responses in people already infected or spread faster than before, or if the disease spreads differently in different segments of a population. Our research suggests that different countries have experienced outbreaks in each of the main possible categories:

O_LISusceptibility-Driven Dynamics with Limited Mitigation [Category A] - in which the disease spread until it infect most people and declined due to low susceptibility levels (i.e., low share of the population still able to be infected).
C_LIO_LISusceptibility-Driven Dynamics Mitigated by Measures [Categories B and C] - in which the disease curve was "flattened" by control measures, but the disease still spread and declined after infecting large numbers of people (but fewer than if there were no mitigation).
C_LIO_LISusceptibility-plus-Measures-Driven Dynamics [Categories D and E] - in which the disease was slowed significantly but not suppressed, i.e., the curve was "flattened" but not "crushed", and the disease is still spreading in the population.
C_LIO_LIMeasures-Driven Dynamics [Categories F and G] - in which the disease has been constrained to date mainly through control measures (social distancing, hygiene and testing & tracing), but, of course, could spread again if measures are relaxed because only a minority of the population has been infected.
C_LIO_LIIndex-Case-Control Dynamics [Category H] - in which the disease has been kept out or suppressed to date through strict control measures (especially quarantines and testing & tracing).
C_LIO_LIComplex Disease Dynamics due to Differences Across Population Segments and/or New Variants [Categories I and J, and many countries in Category K] - in which the disease experienced an apparently susceptibility-driven curve but with low overall infection levels (i.e., share of population infected) because some segments of the population have not had many infections, or in which the disease later shows an unexpected resurgence, due to spreading within the previously less-affected population segments or due to the emergence of immunity-evading strains of the virus.
C_LI

From reported data on COVID-19 cases and disease control measures, we can categorize, for most countries and territories, the dynamics of the disease to date. First, we compare the timing of increases and/or decreases in reported new cases with the timing of changes in the "Stringency Index" of control measures compiled by the Oxford COVID-19 Government Response Tracker - and select the appropriate disease dynamics category. Second, we check if the infection levels expected for the category or categories indicated in the first step, are consistent with predicted ranges from the total numbers of reported cases and deaths using plausible ranges for the case detection rate, death detection rate and infection fatality ratio (IFR) given the countrys income level. This approach yields definitive categories for most countries and territories. COVID-19 disease dynamics are complicated in many countries, due to changes in control measures, seasonal patterns, geographical differences within countries, variability in case testing over time and emergence of new variants; such effects can be seen in the reported cases and deaths for many countries, but they do not obscure the basic drivers of disease dynamics - in other words, which of the categories applies - for most countries.

The results suggest that there is a wide variation in the state of the COVID-19 epidemic around the world - as of 31 January 2021 - as illustrated in the map and the table below. COVID-19 has been suppressed through control measures - Categories F, G and H - in 113 countries and territories with 2.52 billion people or about 32.3% of the global population. However, the rest of the world are in different situations. A total of 31 countries, with populations of 1.45 billion people (18.6% of global population), fall into Categories D and E, meaning that the disease spread has been slowed but not suppressed and cases are currently still increasing or just past their peak. In the 23 countries of Category B, home to 2.05 billion people (26.3%), the disease was slowed but not suppressed, and cases have declined fully from the peak. In a further 9 countries with 0.19 billion people (2.5%), the disease spread through the population after initial waves were suppressed. COVID-19 outbreaks in 5 countries with 0.17 billion people (2.2%) were only somewhat mitigated by control measures and the virus has likely infected most of the population, falling into Category A.

For several countries, which have apparent anomalies and fall outside the "basic" categories, the methodology provides important insights into epidemic status - pointing to situations where significant differences may exist across population segments or providing early warnings of new variants with higher transmissibility or resistance to immunity. For 5 Arabian Peninsula countries (3 of which are in Category I) and Singapore, it is likely that the virus has spread widely among migrant worker communities but has been controlled in the rest of the population. Categories J and K include 28 countries in which reported cases have surged after first waves which were likely or possibly susceptibility-driven, with curves flattened to various extents as a result of control measures which mitigated the epidemics. For some countries - including (1) Kenya, (2) Pakistan, Afghanistan, Kyrgyzstan and Kazakhstan, and (3) Egypt and Sudan - the second peaks are likely due to relaxation of measures but larger than might be expected due to disproportionate effects of the second waves on population segments (likely more affluent groups) which had lower infection levels during the first waves. For other countries - including (1) most countries in Southern Africa and (2) many countries in West Africa - the data suggest the presence of new virus variants with higher transmissibility and possible resistance to immunity, because resurgences or accelerations in cases happened in several neighbouring countries around the same time, and often without changes in control measures, and the second surges in cases usually involved faster increases than the first waves. The B.1.351 variant, with higher transmissibility and some resistance to immunity, was first identified in South Africa and is known to have caused most cases in the countrys second wave; the B.1.1.7 variant, which has higher transmissibility, has been found in Ghana and Nigeria. Several countries in South and Central America have experienced second waves or surges in cases: Surinames might be due to a higher-transmissibility variant (perhaps the P.1 variant that was first identified as coming from the Brazilian Amazon); Bolivias was large but could be explained by a significant decline in control measures; increases in Brazil and several other countries across South and Central America might simply be due to relaxation of social distancing behaviours over the Christmas and New Year holiday season although a role for virus variants cannot be discounted.

Countries of all income levels appear in each of the main disease dynamics categories; however there are clear correlations between income groups and COVID-19 status categories. Most high-income countries have controlled the spread of SARS-CoV-2 through measures (and thus fall in Categories F, G and H). Middle-income countries are spread across all categories, and account for 45 of the 63 countries which have slowed the disease significantly but not fully suppressed it (Categories B, C, D and E). Some low-income countries have experienced largely unmitigated susceptibility-driven dynamics (Category A), while others have "flattened the curve" to varying degrees (Categories B, C, D and E). A mix of low- and middle-income countries are among the 34 countries in Categories J and K.

Clear geographical patterns have emerged in the states of COVID-19 epidemics. There was more diversity in the state of the epidemic within regions earlier in the pandemic, but regional patterns had become clear by the end of January 2021.

O_LIIn the Americas, the disease has spread slowly but has not been suppressed (Categories D and E) in most countries, including those with the largest populations, while many (but not all) of the Caribbean islands have kept SARS-CoV-2 out or under control (Category H).
C_LIO_LIWestern and Northern European countries have, for the most part, controlled the disease through social distancing and hygiene measures, through two or three waves, and fall in Categories F and G.
C_LIO_LIAcross Eastern Europe, the Levant, the Caucuses and Iran, all countries have constrained growth of the disease significantly, but infection levels in most have grown to moderate levels: different countries in these regions are included in Categories C, D/E and F/G, although their infection levels may all be in the moderate range.
C_LIO_LIIn South and Central Asia, the virus has spread widely in most countries and cases have declined. In India, Bangladesh, Nepal and Uzbekistan, the case curve was flattened considerably, and current infection levels are likely moderate (Category B). In Pakistan, Afghanistan, Kyrgyzstan, and Kazakhstan (all in Category J), there have been two peaks in cases. Bhutan has contained the outbreaks of the virus to date (Category F).
C_LIO_LIMany countries in East and South-East Asia have largely kept the disease under control or kept it out (Categories F, G and H). However, Malaysia, Mongolia and Myanmar experienced widespread outbreaks in the second half of 2020, the Philippines appears to be past the peak of its epidemic (Category B), and Indonesia has had a continuous but very slow rise in cases since the start of the pandemic (Category E).
C_LIO_LIIn Australia, New Zealand and most Pacific Island States, SARS-CoV-2 has been excluded through quarantines, together with testing and tracing and lockdowns when the virus has spread beyond quarantined individuals (Categories F and H).
C_LIO_LIAfrican countries appear to have differed greatly in how the disease has spread. Many countries appear to have experienced widespread epidemics followed by declines in case numbers, with varying degrees of "curve flattening" due to control measures (Categories A and B). In some countries - Tunisia, Libya, Togo, Botswana and Mozambique - cases spread very slowly (Categories D and E). A few countries appear to have kept the disease out, and a few others appear to have experienced full outbreaks after having previously kept the virus largely out. As described earlier, most countries in Southern Africa and many in West Africa experienced rapid growth in case numbers in December and January (putting many in Categories J and K) - suggestive of the presence of one or more new variants with higher transmissibility and possible resistance to immunity.
C_LI

We estimate that 1.3-3.0 billion people have been infected by SARS-CoV-2 to date, or about 17-39% of the global population. This estimate is between 13 and 30 times the number of confirmed cases, and perhaps twice to four times as much as previous estimates of total infection numbers. We estimate that 4.6-10.0 million people have died from COVID-19, between 2.1 and 4.5 times the number of deaths attributed to COVID-19.

An estimated 8.9-12.5 million lives remain at risk from COVID-19, which can be saved through appropriate disease control measures and effective deployment of vaccines. Of these estimated extra deaths, if 90% of the population were to contract SARS-CoV-2, high-income countries account for about 2.4-2.9 million, China for about 2.1 million, and India for about 1.7- 2.9 million. Vaccinations, of course, have already started to reduce these numbers substantially.

The findings of this report are backed up by mounting evidence of high infection rates in several low- and middle-income countries. Immunity testing provides direct evidence of the current state of the COVID-19 epidemic. Serological studies in several cities and regions in Brazil, India, Kenya, Pakistan, Qatar and South Africa have already reported finding antibodies for SARS-CoV-2 in large percentages of the studied populations. Note, however, that serological testing will underestimate the number of people who have been infected, due to waning of SARS-CoV-2 antibodies which affects significant numbers of people at about 4-6 months after infection. Consequently, serological testing might understate the actual degree of immunity in a population, because some people may have antibodies at levels below the detection threshold of the serology tests or may have memory B cell or T cell responses, either or both of which will likely reduce the severity of their illness if reinfected, and may reduce their vulnerability to reinfection and their likelihood to pass on the virus to other people if reinfected. In some places, reliable estimates of actual deaths due to COVID-19 may be a substitute for immunity testing to determine the share of population infected to date, at least approximately. Estimates, using a variety of methodologies, in Bolivia, Ecuador, Mexico, Peru, South Africa, Sudan, Syria, Yemen and Zambia all indicate that moderate to high shares of their populations have already been infected.

Different countries should adopt different disease control policies, according to the state of the COVID-19 epidemic in the population. The following recommendations for countries in different categories take into account their current infection levels and the potential for additional infections if measures are relaxed or if new variants become common in a country.

[tpltrtarr]Category A: Control measures should be relaxed for most people; such relaxation is not likely to lead to many more cases and deaths. In some low- and middle-income countries, wealthier population segments may have implemented greater degrees of social distancing during the epidemic to date, and have much lower infection levels than in the overall population; these segments should maintain social distancing, until vaccines arrive, because otherwise they could experience substantial outbreaks (which may have generated "second waves" in some countries). If and when new virus strains with higher transmissibility and/or resistance to immunity arrive, control measures should be strengthened again to avoid new outbreaks, if the new variants cause high mortality levels and if it seems likely that control measures will be more effective at controlling the new outbreaks than they were during the initial outbreaks.
[tpltrtarr]Categories B and C: Control measures currently in place that have the greatest negative health, economic and social consequences could be relaxed. However, many control measures, especially the most effective in limiting virus spread, will need to be maintained, even though current case numbers are low; otherwise, significant resurgences can take place (as has happened, for instance, in Kenya and Bolivia). Population segments that may have maintained lower infection levels during the outbreak to date will need to maintain social distancing. If and when new virus strains with higher transmissibility and/or resistance to immunity arrive, control measures will likely have to be strengthened again to avoid new outbreaks.
[tpltrtarr]Categories D and E: Control measures should be maintained at least until new case numbers fully decline from the peak; if measures are relaxed too soon after cases peak, then significant further outbreaks can be expected (as has happened, for instance, in Brazil, Colombia and Paraguay). Once cases fully decline from the peak - through further infections or as a result of vaccination programmes - then, and only then, some of the disease control measures with the greatest negative health, economic and social consequences could be relaxed. For some countries in Categories D and E, it may be possible to push R0_e below 1 and hence "crush the curve" by introducing some additional control measures or improving compliance with existing measures. New virus strains, especially with higher transmissibility, can generate resurgences or accelerations in growth of cases (as seen, for example, in Mozambique and Togo).
[tpltrtarr]Categories F and G: COVID-19 control measures, put in place by governments and implemented by citizens, have saved perhaps 13.1-14.2 million lives. To continue to protect these lives, control measures need to be maintained until vaccines become widely available - and strengthened, if necessary, to compensate for new virus variants with higher transmissibility.
[tpltrtarr]Category H: Measures to keep the disease out - mainly strict quarantines for new arrivals and testing & tracing of suspected cases - should be maintained until vaccines become widely available.

The findings of this report may have implications for the optimal distribution of early batches of vaccines within countries. Current policies in several countries call for deployment of vaccines first to healthcare workers and then by age cohort, starting with the oldest. These plans are aligned with the results of modelling (by Imperial College London and others) which suggest that, when the supply of vaccines is limited, the optimal strategy is to target the elderly and other high-risk groups. However, the models indicate that, if the supply is sufficient to stop transmission of the virus, the optimal strategy switches to targeting key transmitters (e.g., working age people and potentially children) to indirectly protect the elderly and vulnerable. Consequently, the optimal strategy may vary according to the disease status category for each country:

[tpltrtarr]Category A: Vaccination should concentrate on elderly and vulnerable people, starting with the oldest and most vulnerable. There is no alternative strategy to consider because population-level immunity already exists, and the greatest danger lies in vulnerable people becoming infected due to endemic SARS-CoV-2.
[tpltrtarr]Categories B and C: Vaccinations should probably be given first to elderly and vulnerable groups, and to frontline healthcare and other essential workers. However, if there are resurgences in cases across the population due to higher-transmissibility or immunity-resistant variants, then the optimal strategy may switch to targeting key transmitters, similar to some countries in Categories D and E.
[tpltrtarr]Categories D and E: In some of these countries, the optimal strategy may to be vaccinate key transmitters - while maintaining current disease control measures - because it may be possible to halt the outbreak and "crush the curve", while waiting for further vaccine supplies to arrive (after which disease control measures could be released). This strategy is being pursued by Indonesia and was suggested for the United States of America in a recent paper. However, careful modelling and planning would be necessary, for any country considering such an approach, to determine if a key transmitter strategy would in fact be optimal and if it would be feasible to implement. Further, for such a strategy to work, it will be necessary to keep control measures in place and to keep high-transmissibility variants of the virus out, until enough people have been vaccinated.
[tpltrtarr]Categories F, G and H: Vaccinations should be given first to frontline healthcare and other essential workers and to elderly and vulnerable groups (starting with the oldest and most vulnerable).

These findings may also have implications for the optimal distribution of the first vaccines across countries. Modelling by the Imperial College London COVID-19 Response Team suggests that the optimal allocation of vaccine doses among countries "is sensitive to many assumptions and will vary depending both on the vaccine characteristics and the stage of the epidemic in each country at vaccine introduction," and concluded that, "[g]iven this uncertainty, allocating vaccine doses according to population size appears to be the next most efficient approach." Our findings reinforce the uncertainty strongly: it is very likely that that stage of the epidemic varies greatly across countries. For most countries, the optimal allocation of vaccines doses is likely still to be according to population size - and then for those countries to give doses first to elderly and vulnerable people. However, the global optimal allocation strategy might include providing somewhat greater supplies, during the next few months, to Category D and E countries where using the vaccine to halt spread of the disease might be possible (provided that disease control measures are maintained in those countries). It is clear, in any case, that further modelling of vaccine allocation strategies is essential, taking into account the actual vaccine efficacies and projected available doses by month, as well as allowing for disease stage categories in different countries.

Vaccination strategies will need to account for current and potential future virus variants as well as the likelihood that immunity from vaccination will wane over time. Higher-transmissibility variants of the SARS-CoV-2 virus increase the urgency of distributing vaccines, especially in Category F and G countries which may struggle to keep the disease suppressed, and might cause vaccination of key transmitters to be a less effective strategy for Category D and E countries if higher-transmissibility variants mean that they cant suppress the disease fully with limited vaccinations. Immunity-resistant variants of the virus may reduce the effectiveness of current vaccines, but are not likely to negate fully the protection offered by existing vaccines. Immunity acquired through vaccination is likely to wane over time - like immunity acquired through infection. Looking to the longer term, new virus variants and waning immunity are likely to necessitate re-vaccination (with vaccines effective against the latest variants) on a regular basis. In many, perhaps most, countries, the time to vaccinate the whole population will exceed the timeframe in which immunity from vaccination wanes or new immunity-resistant variants emerge. In making long-term plans, therefore, countries may face a wide range of options for who to vaccinate (elderly and vulnerable populations, key transmitters or entire populations) and for frequency of vaccination (every 6 months, annual, or once if residual benefits are sufficient). Optimal strategies for each country will be complicated to determine, as the choice will depend on many factors, including vaccine effectiveness in reducing mortality and in reducing transmission, how effectiveness wanes over time, mortality rates and transmissibility of new variants (in general and in previously infected or vaccinated people), and, once the risks to life and health from "endemic COVID" decrease to the point where COVID-19 is not an overriding issue, comparison with other health and budgetary priorities.


sentences:
A quantitative risk estimation platform for indoor aerosol transmission of COVID-19 Aerosol transmission has played a significant role in the transmission of COVID-19 disease worldwide. We developed a COVID-19 aerosol transmission risk estimation platform to better understand how key parameters associated with indoor spaces and infector emissions affect inhaled deposited dose of aerosol particles that convey the SARS-CoV-2 virus. The model calculates the concentration of size-resolved, virus-laden aerosol particles in well-mixed indoor air challenged by emissions from an index case(s). The model uses a mechanistic approach, accounting for particle emission dynamics, particle deposition to indoor surfaces, ventilation rate, and single-zone filtration. The novelty of this model relates to the concept of "inhaled & deposited dose" in the respiratory system of receptors linked to a dose-response curve for human coronavirus HCoV-229E. We estimated the volume of inhaled & deposited dose of particles in the 0.5 to 4 m range expressed in picoliters (pL) in a well-documented COVID-19 outbreak in restaurant X in Guangzhou China. We anchored the attack rate with the dose-response curve of HCoV-229E which provides a preliminary estimate of the average SARS-CoV-2 dose per person, expressed in plaque forming units (PFUs). For a reasonable emission scenario, we estimate approximately three PFU per pL deposited, yielding roughly 10 PFUs deposited in the respiratory system of those infected in Restaurant X. To explore the platforms utility, we tested the model with four COVID-19 outbreaks. The risk estimates from the model fit reasonably well with the reported number of confirmed cases given available metadata from the outbreaks and uncertainties associated with model assumptions.

Practical ImplicationsThe model described in this paper is more mechanistic in nature than standard probabilistic models that fail to account for particle deposition to indoor materials, filtration, and deposition of particles in the respiratory system of receptors. As such, it provides added insights into how building-related factors affect relative infection risk associated with inhaled deposited dose. An online version of this mechanistic aerosol risk estimation platform is available at Safeairspaces.com. Importantly, the modular nature of this approach allows for easy updates when new information is available regarding dose-response relationships for SARS-CoV-2 or its variants.


sentences:
Effectiveness of a telerehabilitation program for COVID-19 survivors (TERECO) on exercise capacity, pulmonary function, lower limb muscle strength, and quality of life: a randomised controlled trial ObjectivesTo investigate superiority of a telerehabilitation program for Covid-19 (TERECO) over no rehabilitation with regard to functional exercise capacity, lower-limb muscle strength (LMS), pulmonary function, health-related quality of life (HRQOL), and perceived dyspnoea.

DesignParallel-group randomised controlled-trial with 1:1 block-randomisation.

SettingThree major hospitals from Jiangsu and Hubei provinces, China.

Participants120 Covid-19 survivors with modified Medical Research Council (mMRC) dyspnoea score of 2-3 who had been discharged from hospital were randomised. 61 were allocated to the control group and 59 to the TERECO group.

InterventionThe control group received educational instructions. The TERECO group participated in a 6-week home-based, pulmonary rehabilitation program delivered via smartphone and monitored with chest-worn heart rate telemetry. Exercise types comprised breathing control and thoracic expansion, aerobic exercise, and LMS exercise.

OutcomesPrimary outcome was 6-minute walking distance (6MWD) in metres. Secondary outcomes were LMS measured as squat time in seconds; pulmonary function assessed by spirometry with parameters being forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC, maximum voluntary ventilation (MVV), and peak expiratory flow; HRQOL measured with SF-12 physical component score (PCS) and mental component score (MCS); and mMRC dyspnoea, favourable outcome (no dyspnoea). Outcomes were assessed at 6 weeks (post-treatment) and 28 weeks (follow-up).

Results120 patients were randomised, 15 (12.5%) were lost to follow-up at study endpoint. No serious adverse events occurred. 38 participants in the TERECO group complied with the exercise protocol (64.41% of randomized). The adjusted between-group difference in change in 6MWD from baseline was 65.45 metres (95% CI 43.8-87.1, p<0.001) at post-treatment and 68.62 metres (95% CI 46.39-90.85, p<0.001) at follow-up. Treatment effects for LMS were 20.12 seconds (95% CI 12.34-27.9, p<0.001) post-treatment and 22.23 seconds (95% CI 14.24-30.21, p<0.001) at follow-up. No group differences were found for lung function apart from post-treatment MVV (10.57 litres/minute, 95% CI 0.26-17.88, p=0.005). Increase in SF-12 PCS was greater in the TERECO group with treatment effects estimated as 3.79 (95% CI 1.24-6.35, p=0.004) at post-treatment and 2.69 (95% CI 0.06-5.32, p=0.045) at follow-up. No significant between-group differences were found for improvements in SF-12 MCS. At post-treatment 90.4% endorsed a favourable outcome for mMRC dyspnoea in the TERECO group vs. 61.7% in control (adjusted RR 1.46, 1.17-1.82, p=0.001).

ConclusionsThis trial demonstrated superiority of TERECO over no rehabilitation for 6MWD, LMS, and SF-12 PCS. We found no persistent effects on pulmonary function, SF-12 MCS, and perceived dyspnoea.

Trial registrationChinese Clinical Trial Registry: ChiCTR2000031834, 11 Apr 2020, URL: http://www.chictr.org.cn/showproj.aspx?proj=52216

KEY POINTSO_ST_ABSWhat is already knownC_ST_ABSMany Covid-19 survivors discharged from hospital have reduced exercise capacity, impaired pulmonary function, muscle weakness, and reduced quality of life, all of which might be addressed with pulmonary rehabilitation.

However, evidence on effective pulmonary rehabilitation measures for this population is currently lacking. As delivery of conventional rehabilitation services is furthermore limited due to pandemic control measures, telerehabilitation programs represent a possible alternative.

What the study addsWe developed a telerehabilitation program for Covid-19 survivors (TERECO program) that is delivered via smartphone and can be carried out at home.

Our study suggests that TERECO was safe and participants of the TERECO program had improved exercise capacity, lower-limb muscle strength, and physical quality of life. No relevant group differences were found for lung function, self-reported breathlessness, and mental quality of life.

The TERECO program is inexpensive and could be implemented on a large scale to improve physical health of Covid-19 survivors after discharge from hospital.

labels: respiratory medicine


sentences:
Evaluating strategies to combat a major syphilis outbreak in Australia among Aboriginal and Torres Strait Islander peoples in remote and regional Australia through mathematical modelling. BackgroundAn ongoing infectious syphilis outbreak, first reported among Australian Aboriginal and Torres Strait Islander people in 2011, has resulted in >3000 notifications to the end of 2019 with multiple congenital syphilis cases and infant deaths. In 2017, the Australian Government introduced an enhanced test and treat response. We evaluate the impact of this response and the potential impact of further expansion of testing interventions.

MethodsWe developed a mathematical model to capture the transmission of infectious syphilis among young heterosexual Indigenous Australians aged 15-29 years living in regional and remote areas. We used the model to assess the impact of existing and hypothetical outbreak responses on infectious syphilis prevalence.

FindingsThe increase in testing coverage achieved through the enhanced response (18% coverage in 2011, to 39% in 2019) could lead to a stabilisation of the epidemic from 2021. To return to the pre-outbreak level (<0{middle dot}2%) within five years, testing coverage needs to reach 60%. With the addition of a biannual community-wide screening program, using outreach to test 30% of youth in communities over 6 weeks,, a return to pre-outbreak levels can be achieved within 2 years. If testing coverage alone was scaled-up to 60% at the start of outbreak in 2011, syphilis prevalence would have returned to pre-outbreak levels by 2014.

InterpretationModelling suggests that to control the syphilis outbreak the response needs to be delivered with further potency. The reduction in prevalence could be hastened with community-wide screening at similar time periods across all communities along with increases in annual testing coverage.

FundingThe research was undertaken by the Kirby Institute, UNSW Sydney, for the Multi-jurisdictional Syphilis Outbreak Working Group (MJSO) with funding from the Australian Department of Health.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe search PubMed with the terms (("syphilis"[MeSH Terms] OR "syphilis"[All Fields]) AND ("disease outbreaks"[MeSH Terms] OR ("disease"[All Fields] AND "outbreaks"[All Fields]) OR "disease outbreaks"[All Fields] OR "outbreak"[All Fields])) AND "model "[All Fields]) on 12 March 2020 and identified 27 articles. Most articles focused on men who have sex with men and/or populations with HIV co-infection, neither of which is common in our target population (Indigenous Australians: predominantly aged 15-29; heterosexual and living in regional and remote areas). Of the remaining articles that consider syphilis control through screening interventions, the most relevant paper to our study is a modelling paper by Pourbohloul et al. in 2003, which demonstrated that community-wide treatment has no lasting effect on syphilis transmission.

Added value of this studyWe developed a mathematical model to assess the impact of an enhanced response to a major syphilis outbreak in remote Aboriginal and Torres Strait Islander populations of Australia and whether it can be controlled by increasing testing coverage. The model captures sexual behaviour information and short-term population mobility patterns across regional and remote communities of Australia and was calibrated against the most recent infectious syphilis notification data to-date (up to 2019) and testing coverage data from the affected regions. Our findings provide an insight into the role of increasing testing coverage in controlling syphilis outbreaks among populations living in remote communities globally.

Implications of all the available evidenceExisting evidence suggests that enhanced surveillance, expanded clinical and laboratory services, enhanced health promotion, strengthened community involvement and a rapid outbreak response are core components to controlling syphilis outbreaks. Our study focuses on modelling the impact of expanded clinical services and ability to expand testing among the target population. Our study suggests that increasing testing coverage of the Aboriginal and Torres Strait Islander population aged 15-29 living in remote and regional communities to a level of 60%, would stabilise the epidemic and reduce overall prevalence to pre outbreak levels in around five years. Combining the 60% testing coverage with bi-annual community screening over a 6-week period involving outreach (minimum coverage of 30%) would reduce the time period to around 2 years.

We believe these findings have implications for other Indigenous populations across the world who often live in remote regions with limited access to healthcare and are disproportionately affected by STIs.

labels: sexual and reproductive health


sentences:
Uterine fluid transcriptome as potential non-invasive biomarker for predicting endometrial receptivity BackgroundThe synchrony between the embryo and the receptive endometrium is essential for successful implantation. Therefore, a reliable non-invasive ER prediction method is highly demanded. We aimed to establish a method that could be used to predict endometrium receptivity non-invasively and to evaluate its clinical application potential in patients undergoing IVF.

MethodsThe non-invasive RNA-seq based endometrial receptivity test (nirsERT) was established by sequencing and analyzing the RNA of uterine fluid from 48 IVF patients with normal ER. Subsequently, 22 IVF patients were recruited and analyzed the correlation between the predicted results of nirsERT and pregnancy outcomes.

Results87 marker genes and 3 hub genes were selected to establish the nirsERT. 10-fold cross-validation resulted in a mean accuracy of 93.0%. A small cohort retrospective observation showed that 77.8% (14/18) of IVF patients predicted with normal WOI had successful intrauterine pregnancies, while none of the 3 patients with displaced WOI had successful pregnancy.

ConclusionsnirsERT is potential for a non-invasive, accurate and same cycle testing for ER in reproductive clinic.

FundingFunded by the National Natural Science Foundation of China (grant no. 8187061497) and the National Key Research and Developmental Program of China (grant no. 2018YFC1004800).

Clinical trial numberChiCTR-DDD-17013375.


sentences:
Protocol for disease-oriented Russian disc degeneration study (RuDDS) biobank facilitating functional omics studies of lumbar disc degeneration IntroductionLumbar intervertebral disc degeneration (DD) disease is one of the main risk factors for low back pain. The social and economic importance of low back pain is very high: back pain is among the leading causes of absenteeism and the cost of treating back pain exceeds the cost of treatment of many other serious diseases (cancer, in particular); however, therapy does not always provide the desired result. Despite the variability of biological studies of lumbar DD, it is still not fully understood, partially due to the fact that there are only few studies using systematic and integrative approaches. Hence, more integrative omics studies are needed to link all pieces of knowledge together, build a complete picture of biology of lumbar DD and obtain a deeper understanding of the processes underlying this pathology.

Methods and analysisThis disease-oriented biobank to study lumbar disc degeneration will be recruited from two clinical centers. A total of 1100 participants with available lumbar MRI will be enrolled during the three-year period. General information about a patient, medical history, lumbar MRI parameters and biological material (whole blood and plasma) will be collected in the centers at baseline. Then, from those patients, who will undergo a spine surgery during the treatment, disc tissue samples will be gained. Eventually, postoperative clinical data will be collected from operated patients during the follow-up.

Ethics and disseminationThe study will be performed according to the Helsinki Declaration. The study protocol was approved by the Local Ethical Committee of NRITO ([numero]034/20 dated 02 Oct 2020) and by the Local Ethical Committee of Priorov CITO ([numero]1/21 dated 25 Feb 2021). Preliminary and final results will be presented in peer-reviewed journals, at national and international congresses.

Trial registration numberNCT04600544

ARTICLE SUMMARYO_ST_ABSSTRENGTHS AND LIMITATIONS OF THIS STUDYC_ST_ABSO_LITwo-center and multiple-discipline study: the study includes two centers (Moscow in the European and Novosibirsk in the Asian part of Russia), with research teams specializing in following fields: (1) clinical aspects of lumbar disc degeneration disease, (2) biology and genetics of pain, (3) generation of omics data and (4) multi-omics data analysis
C_LIO_LICollection of variable biological material: whole blood, plasma and, for part of the participants, intraoperative material of the lumbar disc (with different DD status) will be available for omics studies
C_LIO_LIObjective diagnosis: lumbar DD status is confirmed by MRI, not self-reported diagnosis
C_LIO_LISample size is limited compared to nationwide biobanks
C_LIO_LIPatients with severe lumbar DD status will be more prevalent in the biobank than these with mild or no lumbar DD compared to the general population
C_LI


sentences:
Ethical and human subject burdens of trials conducted to evaluate biosimilars Background/AimsWith a policy goal of introducing price competition into the market for biologic drugs after their period of market monopoly is over (called  loss of exclusivity), policymakers created a pathway for companies to make copies of those treatments and termed them  biosimilars. But unlike generic drugs, biosimilar drug copies must be studied in human trials to assure they have the same clinical effect as the original biologic products. The burden that this places on human subject participants, and the opportunity cost on the clinical trial system generally, have not been considered in detail.

MethodsFor all biosimilar drugs in development, approved, or that failed to obtain approval in the US, we abstracted from clinicaltrials.gov registry the number of subjects enrolled at each phase of development.

ResultsWe identified 105 clinical trials for approved or withdrawn biosimilars and another 20 studies that are either planned, ongoing or completed for biosimilars in development. These studies collectively enrolled (or plan to enroll) 38,169 human subjects. Most (28,130) are enrolled in phase 3 studies. The mean number of human subject participants per approval is 1,045, about 25% of the number required for a new drug approval on average.

ConclusionsA consequential number of human subjects are required for the testing of biosimilar drugs prior to approval. The explicit and sole purpose of biosimilars is to induce competition in order to lower prices of biologic drugs after loss of exclusivity. The burden the biosimilar approval trials place on human subjects with no direct clinical benefits but definite risks, and the possibility that they rob subjects from trials that are of more scientific importance, are ones policymakers might consider. Price regulation of biologic drugs after loss of exclusivity could achieve lower prices as well, without the burdens of the current approach.

Funding SourceArnold Ventures (Grant to support Drug Pricing Lab at Memorial Sloan Kettering Cancer Center)

labels: health policy


sentences: Predicting vaccine hesitancy from area-level indicators: A machine learning approach Vaccine hesitancy (VH) might represent a serious threat to the next COVID-19 mass immunization campaign. We use machine-learning algorithms to predict communities at a high risk of VH relying on area-level indicators easily available to policymakers. We illustrate our approach on data from child immunization campaigns for seven non-mandatory vaccines carried out in 6408 Italian municipalities in 2016. A battery of machine learning models is compared in terms of area under the Receiver Operating Characteristics (ROC) curve. We find that the Random Forest algorithm best predicts areas with a high risk of VH improving the unpredictable baseline level by 24% in terms of accuracy. Among the area-level indicators, the proportion of waste recycling and the employment rate are found to be the most powerful predictors of high VH. This can support policy makers to target area-level provaccine awareness campaigns.


sentences: A general computational framework for COVID-19 modelling, with applications to testing varied interventions in education environments We construct a spatially-compartmental individual-based model of the spread of Covid-19 in indoor spaces. The model can be used to predict the infection rates in a variety of locations when various non-pharmaceutical interventions (NPIs) are introduced. Tasked by the Welsh Government, we apply the model to secondary schools and Further and Higher Education environments. Specifically, we consider student populations mixing in a classroom and in halls of residence. We focus on assessing the potential efficacy of Lateral Flow Devices (LFDs) when used in broad-based screens for asymptomatic infection or in  test-to-release scenarios in which individuals who have been exposed to infection are released from isolation given a negative result. LFDs are also compared to other NPIs; we find that, although LFD testing can be used to mitigate the spread of Covid-19, it is more effective to invest in personal protective equipment, e.g. masks, and in increasing ventilation quality. In addition, we provide an open-access and user-friendly online applet that simulates the individual-based model, complete with user tutorials to encourage the use of the model to aid educational policy decisions as input infection data evolves (https://bit.ly/CV19_INTER_IBM).